- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04045665
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG (PACES)
The primary objective of this study is to evaluate the effectiveness (prevention of thromboembolic events) and safety (major bleeding) of adding oral anticoagulation (OAC) to background antiplatelet therapy in patients who develop new-onset post-operative atrial fibrillation (POAF) after isolated coronary artery bypass graft (CABG) surgery.
All patients with a qualifying POAF event, who decline randomization, will be offered the option of enrollment in a parallel registry that captures their baseline risk profile and their treatment strategy in terms of anticoagulants or antiplatelets received. These patients will also be asked to fill out a brief decliner survey.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a prospective, multicenter, open-label, randomized trial comparing OAC with no OAC (1:1 ratio) in patients who develop new-onset POAF after CABG. The primary effectiveness endpoint is the composite of death, ischemic stroke, transient ischemic attack (TIA), myocardial infarction (MI), systemic arterial thromboembolism or venous thromboembolism (VTE) at 90 days after randomization. The primary safety endpoint is BARC (Bleeding Academic Research Consortium) grade 3 or 5 bleeding at 90 days after randomization. The overall intent is to evaluate the trade-off in prevention of thromboembolic events versus an increase in bleeding.
Patients will be randomly assigned to the following treatment strategies:
- OAC-based strategy (experimental arm): OAC with vitamin K antagonist (VKA) with international normalized ratio (INR) target 2-3 or any approved direct oral anticoagulant (apixaban, rivaroxaban, edoxaban or dabigatran) in addition to background antiplatelet therapy with aspirin 75-325mg once-daily or a P2Y12-inhibitor (clopidogrel or ticagrelor)
- Antiplatelet-only strategy (control arm): single antiplatelet therapy with aspirin 75-325mg once-daily or a P2Y12-inhibitor (clopidogrel or ticagrelor)
The protocol-specified duration of anticoagulation is 90 days. Patients, who are randomized to the control arm and develop recurrent AF after 30 days, may be crossed-over to an OAC. Accrual is expected to take 60 months. Study follow-up visits will be performed at 90 days and phone follow-up at days 30, 60, and 180 days.
Data for patients enrolled in the registry will be ascertained from the local clinical site via a review of medical records. The baseline risk profile of registry patients (i.e., patients eligible but unwilling to be randomized) will be analyzed and compared to that of patients randomized in the trial. The usage of anticoagulant and antiplatelet therapies in the registry population overall and baseline CHA2DS2-VASC ischemic stroke risk score will also be determined.
Up to 500 patients will also be offered the option to participate in a digital health substudy which includes a wearable heart rhythm monitor device for 30 days post discharge.
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Ellen Moquete, RN
- Phone Number: 212-659-9651
- Email: ellen.moquete@mountsinai.org
Study Locations
-
-
-
Quebec, Canada, G1V 4G5
- Recruiting
- Hôpital Laval
-
Contact:
- Nathalie Gagne
- Email: Nathalie.Gagne@criucpq.ulaval.ca
-
Principal Investigator:
- Pierre Voisine
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G2B7
- Recruiting
- University of Alberta Hospital
-
Contact:
- Celine Balay
- Email: cbalay@ualberta.ca
-
Principal Investigator:
- Steven Meyer, MD
-
-
Ontario
-
London, Ontario, Canada, N6A 5A5
- Recruiting
- London Health Sciences Centre
-
Contact:
- Stephanie Fox
- Email: Stephanie.Fox@lhsc.on.ca
-
Principal Investigator:
- Michael Chu
-
Ottawa, Ontario, Canada, K1Y 4W7
- Not yet recruiting
- University of Ottawa Heart Institute
-
Contact:
- Jacqueline Fortier
- Email: JFortier@ottawaheart.ca
-
Principal Investigator:
- Marc Ruel
-
Toronto, Ontario, Canada, M4N 3M5
- Recruiting
- Sunnybrook Hospital
-
Contact:
- Reena Karkhanis
- Email: Reena.Karkhanis@sunnybrook.ca
-
Principal Investigator:
- Stephen Fremes
-
Toronto, Ontario, Canada, M5B 1W8
- Not yet recruiting
- Toronto General Hospital
-
Contact:
- Shakira Christie
- Email: Shakira.Christie@uhn.ca
-
Principal Investigator:
- Terrance Yau
-
-
Quebec
-
Montreal, Quebec, Canada, H1T 1C8
- Recruiting
- Montreal Heart Institute
-
Contact:
- Alexandre Bergeron
- Email: alexandre.bergeron.Icm@icm-mhi.org
-
Principal Investigator:
- Denis Bouchard, MD
-
Montreal, Quebec, Canada, H2W 1T8
- Recruiting
- Centre Hospitalier de l'Université de Montréal
-
Contact:
- Joannie Dionne
- Email: joannie.dionne.chum@ssss.gouv.qc.ca
-
Principal Investigator:
- Nicolas Noiseux
-
Montreal, Quebec, Canada, H4J 1C5
- Not yet recruiting
- Hôpital du Sacré-Coeur de Montreal
-
Contact:
- Carole Sirois
- Email: carole.sirois@crhsc.rtss.qc.ca
-
Principal Investigator:
- Hugues Jeanmart
-
-
-
-
-
Bad Neustadt An Der Saale, Germany
- Not yet recruiting
- Clinic Bad Neustadt - Medical Center for Heart and Vascular Diseases
-
Contact:
- Katharina Schoenrath
- Email: kschoenrath@dhzb.de
-
Principal Investigator:
- Anno Diegeler
-
Bad Oeynhausen, Germany
- Not yet recruiting
- HDZ-NRW Bad Oeynhausen
-
Contact:
- Heike Windhagen
- Email: ch-studien@dhz-nrw.de
-
Principal Investigator:
- Kavous Hakim-Meibodi, MD
-
Berlin, Germany
- Recruiting
- German Heart Center Berlin
-
Contact:
- Doris Pickel
- Email: pickel@dhzb.de
-
Principal Investigator:
- Volkmar Falk, MD
-
Berlin, Germany
- Not yet recruiting
- Charité Berlin - Benjamin Franklin Campus
-
Contact:
- Ulf Landmesser, MD
- Email: ulf.landmesser@charite.de
-
Principal Investigator:
- Ulf Landmesser, MD
-
Berlin, Germany
- Not yet recruiting
- Charité Berlin - Rudolf Virchow Campus
-
Contact:
- Burkert Pieske, MD
- Email: burkert.pieske@charite.de
-
Principal Investigator:
- Burkert Pieske, MD
-
Bonn, Germany
- Recruiting
- University Hospital Bonn
-
Principal Investigator:
- Farhad Bakhtiary
-
Contact:
- Sonja Friese
- Email: sonja.friese@ukbonn.de
-
Braunschweig, Germany
- Not yet recruiting
- Medical Center Braunschweig
-
Contact:
- Yessica Peglau
- Email: j.peglau@klinikum-braunschweig.de
-
Principal Investigator:
- Wolfgang Harringer, MD
-
Frankfurt, Germany
- Not yet recruiting
- University Medical Center Frankfurt
-
Contact:
- Heike Strohschnitter
- Email: Heike.Strohschnitter@kgu.de
-
Principal Investigator:
- Thomas Walther, MD
-
Freiburg, Germany
- Not yet recruiting
- Heart Center, University of Freiburg
-
Contact:
- Veronika Blümel, MD
- Email: veronika.bluemel@universitaets-herzzentrum.de
-
Principal Investigator:
- Friedhelm Beyersdorf, MD
-
Heidelberg, Germany
- Not yet recruiting
- University Medical Center Heidelberg
-
Contact:
- Christiane Miesel-Groeschel
-
Principal Investigator:
- Gábor Szabó, MD
-
Kiel, Germany
- Not yet recruiting
- University Medical Center Schleswig-Holstein Kiel
-
Contact:
- Beke Sarrahs
- Email: beke.sarrahs@uksh.de
-
Principal Investigator:
- Assad Haneya, MD
-
Lübeck, Germany
- Not yet recruiting
- University Medical Center Schleswig-Holstein Lübeck
-
Contact:
- Jessika Schmidt
- Email: jessika.schmidt@uksh.de
-
Principal Investigator:
- Stefan Klotz, MD
-
Munich, Germany
- Not yet recruiting
- German Heart Center Munich
-
Contact:
- Stephani Simon
- Email: simons@dhm.mhn.de
-
Principal Investigator:
- Markus Krane, MD
-
Munich, Germany
- Not yet recruiting
- Medical Center of the Ludwig-Maximilians-University Munich
-
Contact:
- Christian Hagl, MD
- Email: christian.hagl@med.uni-muenchen.de
-
Principal Investigator:
- Christian Hagl, MD
-
-
Brandenburg
-
Berlin, Brandenburg, Germany, 11353
- Not yet recruiting
- University Heart Center Hamburg
-
Contact:
- Jutta Nogal
- Email: j.nogal@uke.de
-
Principal Investigator:
- Lennard Conradi, MD
-
Berlin, Brandenburg, Germany, 13347
- Recruiting
- Heart Center Leipzig
-
Principal Investigator:
- Michael Borger, MD
-
Contact:
- Maren Zieger
- Email: Maren.Zieger@leipzig-heart.de
-
-
Lower Saxony
-
Göttingen, Lower Saxony, Germany
- Not yet recruiting
- University Medical Center Göttingen
-
Contact:
- Jessika Jordan
- Email: jessika.jordan@med.uni-goettingen.de
-
Principal Investigator:
- Bernd Danner, MD
-
-
Thuringia
-
Jena, Thuringia, Germany
- Recruiting
- University Medical Center Jena
-
Contact:
- Sabine Krauspe
- Email: sabine.krauspe@med.uni-jena.de
-
Principal Investigator:
- Torsten Doenst, MD
-
-
-
-
-
Bristol, United Kingdom, BS1 3NU
- Recruiting
- University Hospitals Bristol NHS Foundation Trust
-
Contact:
- Emma Hopkins
- Email: emma.hopkins@uhbristol.nhs.uk
-
Principal Investigator:
- Hunaid Vohra
-
Cottingham, United Kingdom, HU16 5JQ
- Recruiting
- Hull University Teaching Hospitals NHS Trust
-
Contact:
- Dumbor Ngaage
- Email: dumbor.ngaage@nhs.net
-
Middlesbrough, United Kingdom
- Recruiting
- South Tees Hospitals NHS Foundation Trust
-
Contact:
- Lynn Whitehouse
- Email: lynn.whitehouse@nhs.net
-
Principal Investigator:
- Ralph White
-
Nottingham, United Kingdom
- Recruiting
- Nottingham University Hospitals NHS Trust
-
Contact:
- Pamela Anderson
- Email: pamela.anderson@nuh.nhs.uk
-
Principal Investigator:
- Anas Boulemden
-
Oxford, United Kingdom, OX3 9DU
- Recruiting
- Oxford University Hospitals NHS Foundation Trust
-
Contact:
- George Krasopoulos
- Email: george.krasopoulos@ouh.nhs.uk
-
Sheffield, United Kingdom
- Recruiting
- Sheffield Teaching Hospitals NHS Foundation Trust
-
Contact:
- Helen Newell
- Email: helen.newell2@nhs.net
-
Principal Investigator:
- Steven Hunter
-
Worthing, United Kingdom, BN11 2DH
- Recruiting
- University Hospitals Sussex NHS Foundation Trust
-
Contact:
- Dawn Martinez
- Email: dawn.diokno@nhs.net
-
Principal Investigator:
- Istiaq M Ahmed
-
-
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72205
- Recruiting
- CHI St. Vincent, Arkansas
-
Contact:
- Lynn Bass
- Email: Lynn.bass@commonspirit.org
-
Principal Investigator:
- Thurston Bauer
-
-
California
-
Los Angeles, California, United States, 90048
- Recruiting
- Cedars-Sinai Medical Center
-
Contact:
- Achille Peiris
- Email: Achille.Peiris@cshs.org
-
Principal Investigator:
- Joanna Chikwe, MD
-
Los Angeles, California, United States, 90033
- Recruiting
- University of Southern California
-
Principal Investigator:
- Vaughn Starnes, MD
-
Contact:
- Ed Lozano
- Email: edwardlo@med.usc.edu
-
Stanford, California, United States, 94305
- Recruiting
- Stanford University
-
Contact:
- Tiffany Flores
- Email: tflores2@stanford.edu
-
Principal Investigator:
- Jack Boyd
-
-
Colorado
-
Aurora, Colorado, United States, 80012
- Active, not recruiting
- Medical Center of Aurora
-
-
Connecticut
-
Danbury, Connecticut, United States, 06810
- Active, not recruiting
- Western Connecticut Hospital Systems
-
New Haven, Connecticut, United States, 06520-8039
- Recruiting
- Yale New Haven
-
Contact:
- Marianne McCarthy
- Email: marianne.mccarthy@yale.edu
-
Principal Investigator:
- Arnar Geirsson
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20010
- Recruiting
- Medstar Washington Hospital Center
-
Principal Investigator:
- Christian Shults, MD
-
Contact:
- Katharine Mahoney
- Email: Katharine.E.Mahoney@medstar.net
-
-
Georgia
-
Atlanta, Georgia, United States, 30308
- Recruiting
- Emory University
-
Contact:
- Mary McBride
- Email: mary.mcbride@emory.edu
-
Principal Investigator:
- Michael Halkos
-
Atlanta, Georgia, United States, 30309
- Recruiting
- Piedmont Healthcare Inc.
-
Contact:
- Amy Autry-Bush
- Email: Amy.Autry-Bush@piedmont.org
-
Principal Investigator:
- Vinod Thourani, MD
-
-
Indiana
-
Fort Wayne, Indiana, United States, 46825
- Recruiting
- Lutheran Medical Center
-
Contact:
- Sharon Eichman
- Email: SEichman@Lutheran-Hosp.com
-
Principal Investigator:
- Vincent Scavo
-
Indianapolis, Indiana, United States, 46202
- Recruiting
- Indiana University
-
Contact:
- Srdjan Kurbalija
- Email: skurbalija@iuhealth.org
-
Principal Investigator:
- Joel Corvera, MD
-
Indianapolis, Indiana, United States, 46260
- Recruiting
- Ascension St. Vincent
-
Contact:
- Jena Stanley
- Phone Number: 317-338-6450
- Email: jena.stanley@ascension.org
-
Principal Investigator:
- David Heimansohn
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70121
- Recruiting
- Ochsner Clinic
-
Contact:
- Nicolle Scholl
- Email: nicolle.scholl@ochsner.org
-
Principal Investigator:
- P. Eugene Parrino
-
-
Maine
-
Portland, Maine, United States, 04102
- Recruiting
- Maine Medical Center
-
Contact:
- Betsey Gallant
- Email: Betsey.Gallant@mainehealth.org
-
Principal Investigator:
- Robert Kramer
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- Recruiting
- University of Maryland
-
Contact:
- Manal Al-Suqi
- Email: MaAl-Suqi@som.umaryland.edu
-
Principal Investigator:
- Mehrdad Ghoreishi, MD
-
Baltimore, Maryland, United States, 21287
- Recruiting
- Johns Hopkins
-
Contact:
- Zyriah Robinson
- Email: zyriah.robinson@jhmi.edu
-
Sub-Investigator:
- James Gammie, MD
-
Principal Investigator:
- Thomas Matthew, MD
-
Bethesda, Maryland, United States, 20814
- Recruiting
- Suburban Hospital
-
Contact:
- Tara Reddy
- Email: treddy4@jh.edu
-
Principal Investigator:
- Thomas Matthew
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Recruiting
- Brigham and Women's Hospital
-
Contact:
- Mariam Kerolos
- Email: mkerolos@bwh.harvard.edu
-
Principal Investigator:
- Sary Aranki
-
Boston, Massachusetts, United States, 02114
- Recruiting
- Massachusetts General Hospital
-
Contact:
- Jenna Barnes
- Email: JBARNES21@mgh.harvard.edu
-
Principal Investigator:
- David D'Alessandro
-
Boston, Massachusetts, United States, 02118
- Recruiting
- Boston Medical Center
-
Contact:
- Darae Ko, MD
- Email: daraeko@bu.edu
-
Principal Investigator:
- Darae Ko, MD
-
Springfield, Massachusetts, United States, 01199
- Active, not recruiting
- Baystate Health
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- Recruiting
- University of Michigan
-
Contact:
- China Green
- Email: chjgreen@med.umich.edu
-
Principal Investigator:
- Jonathan Haft, MD
-
Sub-Investigator:
- Gorav Ailawadi, MD
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Not yet recruiting
- Mayo Clinic
-
Contact:
- Janell Keehn
- Email: keehn.janell@mayo.edu
-
Principal Investigator:
- Juan Crestanello
-
-
Missouri
-
Kansas City, Missouri, United States, 64111
- Recruiting
- Mid America Health Institute
-
Contact:
- Rosann M Gans
- Email: rgans@saint-lukes.org
-
Principal Investigator:
- Keith Allen
-
Saint Louis, Missouri, United States, 63110
- Recruiting
- Washington University School of Medicine
-
Principal Investigator:
- Tsuyoshi Kaneko, MD
-
Contact:
- Annette Irving
- Email: irvinga@wustl.edu
-
-
New Hampshire
-
Lebanon, New Hampshire, United States, 03766
- Recruiting
- Dartmouth-Hitchcock Medical Center
-
Contact:
- Prezley Duncan
- Email: Prezley.M.Duncan@hitchcock.org
-
Principal Investigator:
- Jock McCullough
-
-
New Jersey
-
Neptune, New Jersey, United States, 07753
- Recruiting
- Jersey Shore University Medical Center
-
Contact:
- Lynda Argenzio
- Email: lynda.argenzio@hmhn.org
-
Contact:
- Joanne Kushnir
- Email: Joanne.Kushnir@hmhn.org
-
Principal Investigator:
- Kourosh Asgarian, DO
-
-
New York
-
Bronx, New York, United States, 10467
- Recruiting
- Montefiore Medical Center
-
Contact:
- Magdalena Mamczur-Madry, RN, BSN, MS, ACRP-CP
- Email: mmamczur@montefiore.org
-
Principal Investigator:
- Daniel Goldstein, MD
-
Great Neck, New York, United States, 11023
- Recruiting
- Northwell Health System
-
Principal Investigator:
- Nirav Patel
-
Contact:
- Effe Mihelis
- Email: emihelis@northwell.edu
-
Sub-Investigator:
- Alexander Iribarne
-
New York, New York, United States, 10032
- Recruiting
- Columbia University Medical Center
-
Contact:
- Amanda Alonso
- Email: aa2974@cumc.columbia.edu
-
Principal Investigator:
- Michael Argenziano
-
New York, New York, United States, 10029
- Not yet recruiting
- The Mount Sinai Hospital
-
Contact:
- Stella Palencia
- Email: Stella.Palencia@mountsinai.org
-
Principal Investigator:
- John Puskas
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Recruiting
- Duke University
-
Contact:
- Kathleen Lane
- Email: kathleen.rohrback@duke.edu
-
Principal Investigator:
- Brittany Zwischenberger, MD
-
Greenville, North Carolina, United States, 27858
- Recruiting
- East Carolina University
-
Contact:
- Eddie Hill
- Email: hille19@ecu.edu
-
Principal Investigator:
- Shahab A. Akhter
-
Raleigh, North Carolina, United States, 27610
- Not yet recruiting
- WakeMed
-
Contact:
- Rhonda Norton
- Email: rnorton@wakemed.org
-
Principal Investigator:
- Judson Williams
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Recruiting
- Cleveland Clinic Foundation
-
Contact:
- Denise Kosty-Sweeney
- Email: sweened2@ccf.org
-
Principal Investigator:
- A Marc Gillinov
-
Columbus, Ohio, United States, 43210
- Recruiting
- Ohio State University Medical Center
-
Contact:
- Neha Mali
- Email: neha.mali@osumc.edu
-
Principal Investigator:
- Bryan Whitson
-
-
Oklahoma
-
Tulsa, Oklahoma, United States, 74103
- Recruiting
- Ascension St. John
-
Contact:
- Jane Bryce
- Email: jane.bryce@ascension.org
-
Principal Investigator:
- James Neel, MD
-
-
Pennsylvania
-
Hermitage, Pennsylvania, United States, 16148
- Not yet recruiting
- University of Pittsburgh Medical Center
-
Contact:
- Melissa Enlow
- Email: enlowms@upmc.edu
-
Principal Investigator:
- Robert Kormos
-
Philadelphia, Pennsylvania, United States, 19104
- Recruiting
- University of Pennsylvania
-
Contact:
- Mary Lou Mayer
- Email: MaryLou.Mayer@uphs.upenn.edu
-
Principal Investigator:
- Michael Acker
-
Pittsburgh, Pennsylvania, United States, 15212
- Recruiting
- Allegheny Health Network
-
Contact:
- Christina Horn
- Email: christina.horn@ahn.org
-
Principal Investigator:
- M. Scott Halbreiner, MD
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- Baylor College of Medicine
-
Contact:
- Cuneyt Koksoy
- Email: CUNEYT.KOKSOY@bcm.edu
-
Principal Investigator:
- Todd Rosengart
-
Plano, Texas, United States, 75093
- Recruiting
- Baylor Research Institute
-
Contact:
- Kristen Chionh
- Email: Kristen.Chionh@BSWHealth.org
-
Principal Investigator:
- Michael DiMaio, MD
-
-
Utah
-
Murray, Utah, United States, 84107
- Recruiting
- Intermountain CV Research
-
Contact:
- Erika Hummel
- Email: erika.hummel@imail.org
-
Principal Investigator:
- Stephen McKellar, MD
-
Salt Lake City, Utah, United States, 84112
- Recruiting
- University of Utah
-
Contact:
- Ashley Elmer
- Email: Ashley.Elmer@hsc.utah.edu
-
Principal Investigator:
- Craig Selzman
-
-
Vermont
-
Burlington, Vermont, United States, 05401
- Recruiting
- University of Vermont
-
Contact:
- Amy Henderson
- Email: amy.henderson@uvmhealth.org
-
Principal Investigator:
- Marek Polomsky, MD
-
-
Virginia
-
Charlottesville, Virginia, United States, 22908
- Recruiting
- University of Virginia Health System
-
Contact:
- Ashley Fox
- Email: ATF4C@hscmail.mcc.virginia.edu
-
Principal Investigator:
- Kenan Yount, MD
-
Falls Church, Virginia, United States, 22042
- Active, not recruiting
- INOVA Health
-
-
West Virginia
-
Morgantown, West Virginia, United States, 26506
- Recruiting
- West Virginia University
-
Contact:
- Kimberly Quedado
- Email: kq10006@wvumedicine.org
-
Principal Investigator:
- Vinay Badhwar
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53792
- Recruiting
- University of Wisconsin
-
Contact:
- Melanie Benito
- Email: benito@surgery.wisc.edu
-
Principal Investigator:
- Satoru Osaki, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients of age ≥18 years who undergo isolated CABG for coronary artery disease
- POAF that persists for >60 minutes or is recurrent (more than one episode) within 7 days after the index CABG surgery
Exclusion Criteria:
- Clinical history of either permanent, persistent or paroxysmal atrial fibrillation
- Any pre-existing clinical indication for long-term OAC
- Any absolute contraindication to OAC
Planned use of post-operative dual antiplatelet therapy (DAPT)
a. This includes, but is not limited to, patients with recent PCI with drug-eluting or bare-metal stent.
- Cardiogenic shock
Major perioperative complication* occurring between CABG and randomization
a. including, but not limited to, stroke, TIA, MI, major bleeding (BARC type 4 bleeding), severe sepsis, renal failure requiring dialysis, or need for reoperation due to bleeding (e.g. pericardial tamponade).
- Concomitant left atrial appendage closure during CABG
- Concomitant valve surgery during CABG or prior valve surgery (including aortic, mitral, tricuspid or pulmonary)
- Concomitant mitral valve annuloplasty during CABG
- Concomitant carotid artery endarterectomy during CABG
- Concomitant aortic root replacement during CABG
- Concomitant surgery for AF during CABG
- Liver cirrhosis or Child-Pugh Class C chronic liver disease
- Pharmacologic therapy with an investigational drug or device within 30-days prior to randomization or plan to enroll patient in an investigational drug or device trial during participation in this trial
- Pregnancy at the time of randomization
- Unable or unwilling to provide inform consent
- Unable or unwilling to comply with the study treatment and follow-up
- Existence of underlying disease that limits life expectancy to less than one year
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Antiplatelet Therapy
Antiplatelet-only strategy
|
Aspirin 75-325 mg once-daily or a P2Y12-inhibitor (clopidogrel or ticagrelor)
|
Active Comparator: Oral Anticoagulant
OAC-based strategy
|
OAC with vitamin K antagonist (VKA) with international normalized ratio (INR) target 2-3 or any approved direct oral anticoagulant OR apixaban, rivaroxaban, edoxaban or dabigatran) in addition to background antiplatelet therapy with aspirin 75-325mg once-daily or a P2Y12-inhibitor (clopidogrel or ticagrelor)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Any BARC type 3 or 5
Time Frame: 90 days after randomization
|
The Bleeding Academic Research Consortium (BARC) - any type 3 or 5 bleeding thrombosis and/or pulmonary. Type 3: a. Overt bleeding plus hemoglobin drop of 3 to < 5 g/dL (provided hemoglobin drop is related to bleed); transfusion with overt bleeding b. Overt bleeding plus hemoglobin drop < 5 g/dL (provided hemoglobin drop is related to bleed); cardiac tamponade; bleeding requiring surgical intervention for control; bleeding requiring IV vasoactive agents c. Intracranial hemorrhage confirmed by autopsy, imaging, or lumbar puncture; intraocular bleed compromising vision. type 5: a. Probable fatal bleeding b. Definite fatal bleeding (overt or autopsy or imaging confirmation) |
90 days after randomization
|
Composite of death, ischemic stroke, TIA, MI, systemic arterial thromboembolism or venous thromboembolism (DVT and/or PE)
Time Frame: up to 180 days after randomization
|
Composite score of death, ischemic stroke, transient ischemic attack (TIA), myocardial infarction (MI), systemic arterial thromboembolism or venous thromboembolism (deep venous thrombosis and/or pulmonary embolism).
Composite score calculated by number of events.
|
up to 180 days after randomization
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Net clinical benefit (NCB)
Time Frame: 90 days after randomization
|
Defined as the integration of the trial's primary effectiveness and safety endpoint to capture overall risk and benefit of anticoagulation.
NCB will be assessed as a two-dimensional outcome with the observed NCB plotted versus effectiveness and safety, and a curve drawn.
the confidence intervals will be compared to this curve.
|
90 days after randomization
|
Number of participants with TIA event
Time Frame: 180 days after randomization
|
180 days after randomization
|
|
Number of participants with MI event
Time Frame: 180 days after randomization
|
180 days after randomization
|
|
Number of participants with systematic arterial thromboembolism event
Time Frame: 180 days after randomization
|
180 days after randomization
|
|
Number of participants with venous thromboembolism event
Time Frame: 180 days after randomization
|
180 days after randomization
|
|
Number of cardiovascular mortalities
Time Frame: up to 180 days after randomization
|
up to 180 days after randomization
|
|
Number of non-cardiovascular mortalities
Time Frame: up to 180 days after randomization
|
up to 180 days after randomization
|
|
Number of participants with Ischemic Stroke event
Time Frame: 180 days after randomization
|
180 days after randomization
|
|
The incidence of BARC 2 bleeding at 90 after randomization
Time Frame: 90 days after randomization
|
BARC Type 2: Any clinically overt sign of hemorrhage that "is actionable" and requires diagnostic studies, hospitalization, or treatment by a health care professional
|
90 days after randomization
|
The incidence of BARC 2 bleeding at 180 days after randomization
Time Frame: 180 days after randomization
|
BARC Type 2: Any clinically overt sign of hemorrhage that "is actionable" and requires diagnostic studies, hospitalization, or treatment by a health care professional
|
180 days after randomization
|
Number of cardiac arrhythmias
Time Frame: 180 days after randomization
|
Number of cardiac arrhythmias including recurrent symptomatic or asymptomatic AF requiring medical attention
|
180 days after randomization
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Annetine C Gelijns, PhD, Icahn School of Medicine at Mount Sinai
- Study Director: Marc Gillinov, MD, The Cleveland Clinic
- Study Director: John Alexander, MD, Duke University
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GCO 08-1078
- 2U01HL088942-12 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stroke
-
University Hospital, GhentRecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Stroke HemorrhagicBelgium
-
Moleac Pte Ltd.RecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, CryptogenicSingapore, Philippines
-
Moleac Pte Ltd.Not yet recruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, Cryptogenic
-
IRCCS San Camillo, Venezia, ItalyRecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke HemorrhagicItaly
-
Vanderbilt University Medical CenterPatient-Centered Outcomes Research Institute; University of Alabama at BirminghamEnrolling by invitationStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Engagement, Patient | Stroke HemorrhagicUnited States
-
University of MinnesotaAmerican Occupational Therapy FoundationRecruitingStroke | Stroke Sequelae | Stroke Hemorrhagic | Stroke IschemicUnited States
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); Michael Smith Foundation for...RecruitingStroke | Stroke, Ischemic | Stroke Hemorrhagic | Chronic StrokeCanada
-
University of CincinnatiMedical University of South Carolina; University of California, Los Angeles; University...RecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke HemorrhagicUnited States
-
University of LiegeCompletedStroke, Acute | Stroke Hemorrhagic | Stroke, ComplicationBelgium
-
Turkish Stroke Research and Clinical Trials NetworkElectroCore INC; Turkish Neurological SocietyCompletedStroke | Stroke, Ischemic | Stroke, Acute | Stroke, HemorrhagicTurkey
Clinical Trials on Antiplatelet-only strategy
-
Seoul National University HospitalLudwig-Maximilians - University of Munich; ST. Antonius hospital NieuwegeinRecruitingCoronary Artery Disease | Acute Coronary SyndromeKorea, Republic of
-
National Institute of Cardiology, Warsaw, PolandRecruitingCoronary Artery Disease | Total Occlusion of Coronary ArterySpain, France, Hungary, Czechia, Poland, Austria, Croatia, Germany, Israel, Italy, Romania
-
NYU Langone HealthRecruiting
-
Josep Rodes-CabauRecruitingIschemic Stroke | Patent Foramen Ovale | Bleeding UlcerCanada
-
Institute of Cardiology, Warsaw, PolandMedical Research Agency, PolandRecruitingAtrial FibrillationPoland
-
Hospices Civils de LyonNot yet recruiting
-
China National Center for Cardiovascular DiseasesUnknown
-
Centre Hospitalier Universitaire de NīmesCompletedCentral Venous CatheterizationFrance
-
Assistance Publique - Hôpitaux de ParisMinistry of Health, FranceCompleted
-
Yale UniversityNational Institute of Allergy and Infectious Diseases (NIAID); National Heart...CompletedTuberculosis | Tuberculosis, PulmonaryUganda